- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 BID Versus Placebo Twelve-week Efficacy Study (clinicaltrials.gov) - Feb 6, 2014 P3, N=432, Completed, Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Trial termination: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014 P4, N=41, Terminated, Recruiting --> Active, not recruiting Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up
- |||||||||| micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Enrollment change: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014 P4, N=41, Terminated, Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up N=80 --> 41
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 Versus Placebo 12-week Efficacy Study (clinicaltrials.gov) - Jan 13, 2014 P3, N=440, Completed, N=80 --> 41 Active, not recruiting --> Completed
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Enrollment open: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Mar 17, 2013 P=N/A, N=104, Recruiting, Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| apomorphine inhalational (VR 040) / Vectura, Kyowa Kirin
New P2 trial, Metastases: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease (EUDRACT) - Jan 22, 2012 P2, N=24, Ongoing,
|